These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 28274140)

  • 101. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 102. An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
    Brunton SA
    J Fam Pract; 2018 Jun; 67(6 suppl):S3-S7. PubMed ID: 29912995
    [TBL] [Abstract][Full Text] [Related]  

  • 103. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch
    Asakura T; Suzuki S; Aranishi T; Cai Z
    Curr Med Res Opin; 2018 Jun; 34(6):1117-1124. PubMed ID: 29504812
    [TBL] [Abstract][Full Text] [Related]  

  • 105. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
    Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE
    Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
    Drab SR
    Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.
    Shi Y; Liu S; Zhu J; Hong T
    J Diabetes; 2021 Apr; 13(4):353-357. PubMed ID: 33325105
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
    Bajaj HS; Gerstein HC; Rao-Melacini P; Basile J; Colhoun H; Conget I; Cushman WC; Dagenais GR; Franek E; Hanefeld M; Keltai M; Lakshmanan M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Probstfield J; Raubenheimer P; Ryden L; Shaw JE; Sheu WH; Xavier D
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):484-490. PubMed ID: 34153269
    [TBL] [Abstract][Full Text] [Related]  

  • 109. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
    Wysham C; Guerci B; D'Alessio D; Jia N; Botros FT
    Diabetes Obes Metab; 2016 Nov; 18(11):1138-1142. PubMed ID: 27265893
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
    Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
    J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
    [No Abstract]   [Full Text] [Related]  

  • 112. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Pozzilli P; Leslie RD; Peters AL; Buzzetti R; Shankar SS; Milicevic Z; Pavo I; Lebrec J; Martin S; Schloot NC
    Diabetes Obes Metab; 2018 Jun; 20(6):1490-1498. PubMed ID: 29377522
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Two new GLP-1 receptor agonists for diabetes.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
    [No Abstract]   [Full Text] [Related]  

  • 116. Dulaglutide: A Review in Type 2 Diabetes.
    Scott LJ
    Drugs; 2020 Feb; 80(2):197-208. PubMed ID: 32002850
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
    Arslanian SA; Hannon T; Zeitler P; Chao LC; Boucher-Berry C; Barrientos-Pérez M; Bismuth E; Dib S; Cho JI; Cox D;
    N Engl J Med; 2022 Aug; 387(5):433-443. PubMed ID: 35658022
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
    Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
    [TBL] [Abstract][Full Text] [Related]  

  • 119. A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
    Li H; Xu X; Wang J; Kong X; Chen M; Jing T; Zhang Z; Yin G; Liu X; Hu Y; Ye L; Su X; Ma J
    J Diabetes Res; 2019; 2019():6423987. PubMed ID: 31183384
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.